Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Mesoblast Limited (MESO) Price & Performance

KraneShares Electric Vehicles and Future MobilityTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

KraneShares Electric Vehicles and Future Mobility vs Mesoblast Limited — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $29.85, while Mesoblast Limited trades at $16.36 (market cap $2.17B). Which is the better fit depends on your goals.

KARSMESO
Sector
Sector/ThematicTechnology
52-Week High
$38.01$20.96
52-Week Low
$23.61$12.88
Market Cap
$2.17B
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KraneShares Electric Vehicles and Future Mobility

KARS trades at $29.15, down 0.98% with a bearish technical signal from moving averages and oscillators showing mixed signals. The stock faces headwinds from sector rotation away from traditional automakers toward efficient vehicles, as highlighted by recent news. Financial ratios are unavailable, limiting fundamental clarity, but the electric vehicle ETF context suggests exposure to evolving industry dynamics.

Outlook remains cautious due to technical weakness and sector pressures, though potential exists if EV adoption accelerates. Risks include competitive threats from Chinese automakers and regulatory uncertainty. Investors should await clearer financial data to assess valuation and growth prospects amid shifting market sentiment.

Mesoblast Limited

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

Returns comparison

Trailing returns across standard periods

About KraneShares Electric Vehicles and Future Mobility

KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.

Read more on KARS

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO